

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CANbridge Pharmaceuticals Inc.

北海康成製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1228)

INSIDE INFORMATION

VELAGLUCERASE-BETA FOR INJECTION (GAURUNNING, CAN103) OBTAINED MARKETING APPROVAL IN THE PRC

This announcement is made by CANbridge Pharmaceuticals Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company hereby informs the shareholders and potential investors of the Company that velaglucerase-beta for injection (Gaurunning, CAN103) has been granted marketing approval by the National Medical Products Administration (the “**NMPA**”) of the People’s Republic of China (the “**PRC**”) for treatment of type I and III Gaucher disease on May 15, 2025. The Company holds global proprietary rights to develop and commercialize the product.

INFORMATION ABOUT GAUCHER DISEASE

Gaucher disease, one of the most common lysosomal storage disorders, is a rare inherited genetic metabolic disease caused by autosomal recessive mutations in the GBA gene located on chromosome 1q22 and affects both males and females equally. Gaucher disease is a clinical spectrum that comprises Type 0 (perinatal-lethal), Type I (chronic non-neuronopathic), Type II (acute neuronopathic), and Type III (chronic neuronopathic) forms, with Types I and III surviving into adulthood. Gaucher disease is caused by a deficiency of glucocerebrosidase (acid b-glucosidase), an enzyme that helps break down a cellular membrane glycosphingolipid called glucocerebroside (glucosylceramide) inside lysosomes. As a result, glucocerebroside accumulates primarily in cells of the monocyte-macrophage lineage (Gaucher cells) within certain organs, leading to splenomegaly, hepatomegaly, anemia, thrombocytopenia, bone pain and fractures, and in the most severe forms (perinatal-lethal, Types II and III), early neurological symptoms.

INFORMATION ABOUT GAURUNNING

Gaurunning is the first domestically independently developed long-term enzyme replacement therapy for adolescents aged 12 and above and adults with type I and type III Gaucher disease. As a Class 1 innovative drug, it can fully replace similar imported products and will significantly enhance medication accessibility for domestic patients.

INFORMATION ABOUT THE COMPANY

The Company is a global biopharmaceutical company, with a foundation in the PRC, committed to the research, development and commercialization of transformative therapies for rare disease. The Company has a differentiated drug portfolio, with three approved drugs and a pipeline of eight assets, targeting prevalent rare disease indications that have unmet needs and significant market potential. These include Hunter syndrome and other lysosomal storage disorders, complement-mediated disorders, hemophilia A, metabolic disorders, rare cholestatic liver diseases and neuromuscular diseases. The Company is developing novel, potentially curative, gene therapies for rare genetic diseases including Duchenne muscular dystrophy (DMD), and collaborates with world-leading researchers and biotech companies.

Warning under Rule 18A.08(3) of the Listing Rules: There is no assurance that velaglucerase-beta for injection (Gaurunning, CAN103) will ultimately be successfully commercialized by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
CANbridge Pharmaceuticals Inc.
北海康成製藥有限公司
Dr. James Qun Xue
Chairman

Hong Kong, May 20, 2025

As of the date of this announcement, the Board comprises Dr. James Qun Xue as Chairman and executive Director, Dr. Fangxin Li as non-executive Director, and Dr. Richard James Gregory, Mr. James Arthur Geraghty, Mr. Peng Kuan Chan and Dr. Lan Hu as independent non-executive Directors.